Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Consolidated Net Income (2016 - 2025)

Iovance Biotherapeutics has reported Consolidated Net Income over the past 13 years, most recently at -$71.9 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at -$71.9 million for Q4 2025, up 8.43% from a year ago — trailing twelve months through Dec 2025 was -$391.1 million (down 5.07% YoY), and the annual figure for FY2025 was -$391.0 million, down 5.05%.
  • Consolidated Net Income for Q4 2025 was -$71.9 million at Iovance Biotherapeutics, up from -$91.3 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for IOVA hit a ceiling of -$71.9 million in Q4 2025 and a floor of -$116.4 million in Q4 2023.
  • Median Consolidated Net Income over the past 3 years was -$106.9 million (2023), compared with a mean of -$100.6 million.
  • Biggest five-year swings in Consolidated Net Income: soared 32.47% in 2024 and later fell 15.0% in 2025.
  • Iovance Biotherapeutics' Consolidated Net Income stood at -$116.4 million in 2023, then skyrocketed by 32.47% to -$78.6 million in 2024, then grew by 8.43% to -$71.9 million in 2025.
  • The last three reported values for Consolidated Net Income were -$71.9 million (Q4 2025), -$91.3 million (Q3 2025), and -$111.7 million (Q2 2025) per Business Quant data.